We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

RXST:NASDAQRxSight, Inc. Analysis

Data as of 2026-05-23 - not real-time

$6.09

Latest Price

8/10Risk

Risk Level: High

Executive Summary

RxSight’s stock is trading well below its 20‑day (6.37), 50‑day (6.70) and 200‑day (8.66) moving averages, signaling a sustained bearish price trend. The RSI of 44 hints at a neutral‑to‑bearish momentum, while the MACD histogram shows a modest bullish tilt that has not yet translated into price recovery. Revenue has contracted 18% year‑over‑year to $30.9 M and operating margins remain deep in the red (‑57%), yet the company boasts a strong cash cushion of $218 M against modest debt of $10.8 M, giving it runway to fund R&D and market expansion. Recent milestones—over 300,000 Light Adjustable Lens implants and a modest EPS surprise—provide a narrative of commercial traction, but high volatility (68% 30‑day) and a beta of 1.6 underscore heightened market risk.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish technical positioning below key moving averages
  • Elevated volatility and beta increasing price swings
  • Negative cash flow and operating losses limiting near‑term upside

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Milestone of 300k LAL implants indicating market adoption
  • Substantial cash reserves to support product rollout and FDA activities
  • Analyst price targets clustering around $9‑$10, implying ~44% upside

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Unique, adjustable intra‑ocular lens technology with differentiated value proposition
  • Potential for revenue growth as cataract surgery volumes recover post‑pandemic
  • Undervalued book value (P/B < 1) offering a margin of safety over a multi‑year horizon

Key Metrics & Analysis

Financial Health

Revenue Growth-18.50%
Profit Margin-36.59%
P/E Ratio-10.9
ROE-17.06%
ROA-11.21%
Debt/Equity4.05
P/B Ratio0.9
Op. Cash Flow$-17570000
Free Cash Flow$-969250
Industry P/E27.6

Technical Analysis

TrendBearish
RSI43.9
Support$5.30
Resistance$7.49
MA 20$6.37
MA 50$6.70
MA 200$8.66
MACDBullish
VolumeDecreasing
Fear & Greed Index91.61

Valuation

Target Price$8.79
Upside/Downside44.38%
GradeUndervalued
TypeBlend

Risk Assessment

Beta1.59
Volatility68.07%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.